{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:27:14Z","timestamp":1761182834964,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/s10156-013-0602-0","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T07:26:30Z","timestamp":1371626790000},"page":"1188-1192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report"],"prefix":"10.1016","volume":"19","author":[{"given":"Pei-ling","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-guo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-013-0602-0_bib0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"Marcellin","year":"2009","journal-title":"J Hepatol"},{"key":"10.1007\/s10156-013-0602-0_bib0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1007\/s10156-013-0602-0_bib0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","article-title":"Peg-interferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis","volume":"46","author":"Buster","year":"2007","journal-title":"Hepatology"},{"key":"10.1007\/s10156-013-0602-0_bib0020","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"key":"10.1007\/s10156-013-0602-0_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1007\/s10156-013-0602-0_bib0030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1007\/s10156-013-0602-0_bib0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2011.01465.x","article-title":"Hepatitis B surface antigen monitoring and management of chronic hepatitis B","volume":"18","author":"Sonneveld","year":"2011","journal-title":"J Viral Hepatitis"},{"key":"10.1007\/s10156-013-0602-0_bib0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0030-1267537","article-title":"Management of chronic hepatitis B: status and challenges beyond treatment guidelines","volume":"30","author":"Johannes","year":"2010","journal-title":"Semin Liver Dis"},{"key":"10.1007\/s10156-013-0602-0_bib0045","first-page":"180","article-title":"Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection","volume":"65","author":"Guner","year":"2012","journal-title":"J Infect"},{"key":"10.1007\/s10156-013-0602-0_bib0050","first-page":"1211","article-title":"Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis","volume":"55","author":"Yasunaka","year":"2011","journal-title":"J Hepatol"},{"key":"10.1007\/s10156-013-0602-0_bib0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5812\/hepatmon.5124","article-title":"Hepatitis B immune globulin in liver transplantation prophylaxis: an update","volume":"12","author":"Dindoost","year":"2012","journal-title":"Hepat Mon"},{"key":"10.1007\/s10156-013-0602-0_bib0060","first-page":"119","article-title":"Efficacy of hepatitis B vaccine in those who lost hepatitis B surface antigen during follow-up","volume":"11","author":"Taheri","year":"2011","journal-title":"Hepat Mon"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1370028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1370028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10156-013-0602-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:49:46Z","timestamp":1761158986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X1370028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"alternative-id":["S1341321X1370028X"],"URL":"https:\/\/doi.org\/10.1007\/s10156-013-0602-0","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-013-0602-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}